is semaglutide on the shortage list FDA Ends Listing, Contributing to Ongoing Legal Challenges Ozempic and Wegovy removed from

Somatostatin-14 is mainly found in the central nervous system and pancreatic islets, where it plays a crucial role in inhibiting the release of growth hormone, insulin, glucagon, and other hormones

[DOI] [PMC free article] [PubMed] [Google Scholar] 49.Apostolova N., Vezza T., Muntane J., Rocha M., Vctor V.M

there are ways to address common issues and improve your chances on appeal: Income slightly over limit : If your household income is just above the eligibility threshold, ask your healthcare provider to write a detailed appeal letter explaining your financial situation and medical need

Approximately 14 states cover GLP-1 medications for weight loss as of 2025, typically with extensive prior authorization requirements

Solving Cost and Access Barriers The price is one of the major barriers to GLP-1 weight-loss therapy

Who GLP-1 Therapy May Be Appropriate For (Self-Assessment Framework) Rather than presenting testimonialswhich can reflect self-selection bias and individual experiences that may not be typicalthis framework helps you evaluate whether pursuing a GLP-1 consultation heading into 2026 may align with your situation